20, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Tom Glawdel, PhD as Chief Scientific Officer and HemoPalm science lead effective immediately.
Mr. Glawdel is a decorated PhD in Mechanical and Mechatronics Engineering from the University of Waterloo with experience in the development of microfluidic, molecular diagnostics, RUO products and medical devices both internal and through strategic research partnerships. Tom has authored 30+ academic publications and patent applications.
“I am very happy to be welcoming Tom to the team as Chief Scientific Officer and Science lead for the HemoPalm platform” said Lahav Gil, CEO, ChroMedX Corp. “Tom has a rare combination of scientific and engineering training, combined with core knowledge in microfluidics and biosensors development. On top of that he has a great understanding of commercialization strategies and business considerations. This makes him an excellent leader and team member in a MedTech incubator-accelerator like ours. Beyond that, his ability to manage the thinking process around complex issues and bring clarity to the discussion is remarkable”.
As Chief Scientific Officer and HemoPalm lead, Tom will be responsible for managing the development of the Company’s sensor technologies and the single use cartridge for the HP, as well as provide key scientific input into additional projects and products as the Company expands. He is currently building out the lab, accelerating HP prototype development, and managing the IP portfolio.
Tom began his career in the industry at STEMCELL Technologies in Bioengineering R&D, developing novel technologies for cell separation and purification, and cell culture for the stem cell research market.
Following this, Tom held escalating positions at Xagenic Inc.; a privately held molecular diagnostics company developing a fully-automated molecular diagnostic platform. Tom assisted in managing research initiatives and product development for a team of 20 researchers, developed data analytics methods and tools for processing experimental data across research, quality and manufacturing groups, and guided research and development of a novel molecular diagnostic platform.
The Company also announces that it has granted an aggregate of 4,017,500 options to purchase common shares of the Company exercisable at todays closing price and expiring on June 21, 2023, to certain directors, officers, employees and consultants of the Company
|
Thread abonnieren
